幹細胞治療の世界市場：市場規模・シェア分析 (種類別・細胞の供給源別・用途別)、産業需要の予測 (～2030年)

世界の幹細胞治療の市場規模は、2023年には3億610万米ドル、2030年には9億1,080万米ドルに達します。

成長促進要因

市場成長の主な要因は、整形外科疾患・外傷・神経疾患、自己免疫疾患 (狼瘡、多発性硬化症、COPD、脳卒中、パーキンソン病、ALSなど) の罹患率の増加です。

また、幹細胞治療への関心が高まるにつれ、幹細胞バンクへのニーズも高まっており、将来の市場拡大の原動力となると思われます。

さらに、研究の進展やオーダーメイド薬への注目が高まっていることも、今後数年間の業界の原動力となると思われます。

同種幹細胞治療が最大のシェア

2023年には同種幹細胞治療が60%の最大シェアを占め、2024年から2030年にかけては17%の速度で増加すると予想されます。

これは、この種の治療を進めるための臨床試験の件数が増加しているためです。

同種移植の最大の利点は、移植片に混入する腫瘍細胞がないことです。移植片はまた、ドナーから得られた免疫担当細胞から構成され、免疫移植片対悪性腫瘍効果を開始する可能性があります。

北米が最大の収益シェアを占める

北米は、2023年時点で55%のシェアを占め、地域別で市場のリーダーとなり、10年間の分析期間の末には大きく成長すると思われます。

これは、この地域で幹細胞治療の開発に投資が行われているためです。

アジア太平洋地域が最も急成長

アジア太平洋地域は最も急成長しており、中でも中国は幹細胞治療に力を入れている重要な国です。

当レポートでは、世界の幹細胞治療の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、種類別・細胞の供給源別・用途別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：種類別 (2017～2030年)
• 市場収益：細胞の供給源別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：種類別 (2017～2030年)
• 市場収益：細胞の供給源別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ (MEA) 市場

第12章 米国市場

• 概要
• 市場収益：種類別 (2017～2030年)
• 市場収益：細胞の供給源別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Smith & Nephew plc
• MEDIPOST Co. Ltd.
• Anterogen Co. Ltd.
• CORESTEM Inc.
• PHARMICELL Co. Ltd.
• NuVasive Inc.
• RTI Surgical Inc.
• AlloSource
• JCR Pharmaceutical Co. Ltd.
• Takeda Pharmaceutical Company Limited

第31章 付録

The size of the stem cell therapy market was USD 306.1 million in 2023, and it will touch USD 910.8 million in 2030, with a rate of 16.9% throughout the projection period.

Growth Drivers

The key factors responsible for the advance of the market are the growing incidence of orthopedic conditions, traumatic injuries, neurological ailments, and autoimmune diseases, such as lupus, multiple sclerosis, COPD, stroke, Parkinson's disease, and ALS.

Also, with the growing familiarity of stem cell therapy, the rising requirement for stem cell banking will power the market in the future.

Moreover, the growing advances in research and a rising emphasis on customized medications will power the industry in the years to come as well.

For example, in November 2022, USD 8 million was invested by the California Institute for Regenerative Medicine in the UC San Diego Alpha Stem Cell Clinic for allowing the latter to create more-efficient stem cell therapies for the diseases, which are difficult to treat.

Allogeneic Stem Cell Therapy had the Largest Share

The largest share of 60% was held by the Allogeneic stem cell therapy in 2023, and it will power at a rate of 17% during 2024-2030.

This is because of the growth in the count of clinical trials for the advance of these kinds of treatments.

The foremost advantage of allogeneic transplantation is that there is not any contaminating tumor cell in the graft. The graft also comprises immunocompetent cells resultant from a donor, which might initiate an immune graft-against-malignancy effect.

Autologous Therapy To Grow Significantly

The autologous therapy category will have a significant growth in the future due to the little risk of rejection of graft in this treatment. People requiring high-dose of chemotherapy and radiation are frequently transplanted with autologous stem cells for replacing the bone marrow damaged by the main treatment.

Furthermore, more than a few studies, conducted in recent times are focusing on autologous HSCT have shown optimistic results for secondary progressive multiple sclerosis. The method makes use of healthy blood stem cells from the own body of a person for replacing diseased cells.

North America to have Largest Revenue Share

North America was the leader of the regional market, with a share of 55%, in 2023, and it will grow significantly by the end of this decade.

This is due to the investment being provided for the development of stem cell therapies in this region.

For example, in September 2022, a gene-therapy-focused contract development and manufacturing company Forge Biologics Inc, publicized that it has acquired a total amount of USD 90 million in a Series C financing round co-led by Drive Capital and Aisling Capital, with another unrevealed strategic investor.

APAC Region To Grow the Fastest

Ther APAC region is observing the fastest-growth, with China being a key nation concentrating on stem cell therapy.

For example, OBiO Technology Corp. Ltd., a Shanghai-based gene-and-cell-therapy-focused CRO and CDMO in January 2023, publicized that the FDA has acknowledged its GMP plasmid drug master file filings for autologous and allogenic cell therapy and stem cell therapy products and helps in reducing the time taken in communication, assessment, and analysis of the filings for related therapeutics on part of the FDA.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by type
  • 1.4.2. Market size breakdown, by cell source
  • 1.4.3. Market size breakdown, by application
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Type (2017-2030)
• 6.3. Market Revenue, by Cell Source (2017-2030)
• 6.4. Market Revenue, by Application (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Type (2017-2030)
• 7.3. Market Revenue, by Cell Source (2017-2030)
• 7.4. Market Revenue, by Application (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Type (2017-2030)
• 8.3. Market Revenue, by Cell Source (2017-2030)
• 8.4. Market Revenue, by Application (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Type (2017-2030)
• 9.3. Market Revenue, by Cell Source (2017-2030)
• 9.4. Market Revenue, by Application (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Type (2017-2030)
• 10.3. Market Revenue, by Cell Source (2017-2030)
• 10.4. Market Revenue, by Application (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Type (2017-2030)
• 11.3. Market Revenue, by Cell Source (2017-2030)
• 11.4. Market Revenue, by Application (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Type (2017-2030)
• 12.3. Market Revenue, by Cell Source (2017-2030)
• 12.4. Market Revenue, by Application (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Type (2017-2030)
• 13.3. Market Revenue, by Cell Source (2017-2030)
• 13.4. Market Revenue, by Application (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Type (2017-2030)
• 14.3. Market Revenue, by Cell Source (2017-2030)
• 14.4. Market Revenue, by Application (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Type (2017-2030)
• 15.3. Market Revenue, by Cell Source (2017-2030)
• 15.4. Market Revenue, by Application (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Type (2017-2030)
• 16.3. Market Revenue, by Cell Source (2017-2030)
• 16.4. Market Revenue, by Application (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Type (2017-2030)
• 17.3. Market Revenue, by Cell Source (2017-2030)
• 17.4. Market Revenue, by Application (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Type (2017-2030)
• 18.3. Market Revenue, by Cell Source (2017-2030)
• 18.4. Market Revenue, by Application (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Type (2017-2030)
• 19.3. Market Revenue, by Cell Source (2017-2030)
• 19.4. Market Revenue, by Application (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Type (2017-2030)
• 20.3. Market Revenue, by Cell Source (2017-2030)
• 20.4. Market Revenue, by Application (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Type (2017-2030)
• 21.3. Market Revenue, by Cell Source (2017-2030)
• 21.4. Market Revenue, by Application (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Type (2017-2030)
• 22.3. Market Revenue, by Cell Source (2017-2030)
• 22.4. Market Revenue, by Application (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Type (2017-2030)
• 23.3. Market Revenue, by Cell Source (2017-2030)
• 23.4. Market Revenue, by Application (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Type (2017-2030)
• 24.3. Market Revenue, by Cell Source (2017-2030)
• 24.4. Market Revenue, by Application (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Type (2017-2030)
• 25.3. Market Revenue, by Cell Source (2017-2030)
• 25.4. Market Revenue, by Application (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Type (2017-2030)
• 26.3. Market Revenue, by Cell Source (2017-2030)
• 26.4. Market Revenue, by Application (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Type (2017-2030)
• 27.3. Market Revenue, by Cell Source (2017-2030)
• 27.4. Market Revenue, by Application (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Type (2017-2030)
• 28.3. Market Revenue, by Cell Source (2017-2030)
• 28.4. Market Revenue, by Application (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Smith & Nephew plc
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. MEDIPOST Co. Ltd.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Anterogen Co. Ltd.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. CORESTEM Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. PHARMICELL Co. Ltd.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. NuVasive Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. RTI Surgical Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. AlloSource
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. JCR Pharmaceutical Co. Ltd.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Takeda Pharmaceutical Company Limited
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports